Corcept Therapeutics, based in Menlo Park, California, is a commercial-stage pharmaceutical company that markets Korlym for Cushing's syndrome and has a portfolio of selective cortisol modulators. Founded in 2004, it employs 352 people and offers around 1,000 compounds.
William Guyer sold 20,000 shares of CORT on 10 June at $72.75 per share, worth a total of $1.5M. They now own 8,569 CORT shares, or a 78% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
